ArticleFrontiers in endocrinology2025
Association of baseline osteocalcin and femoral neck bone mineral density in healthy women with future risk of fractures, cardiovascular disease, diabetes and death.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to explore relationships between baseline bone metabolism markers and long-term outcomes, collectively referred to as fractures, cardiovascular diseases, diabetes and all-cause death (FCDD), in healthy women at baseline and identify predictive markers for outcome. Methods: This study included 356 healthy women and assessed baseline bone turnover markers-osteocalcin, C-telopeptide of type I collagen-as well as bone mineral densities (BMDs) at lumbar spine (L1-4), femoral neck (FN) and total hip (TH). A 16-year retrospective follow-up via telephone questionnaire tracked FCDD occurrence. Statistical tests, including univariate analysis, forward stepwise regression and logistic regression analysis, were used to determine correlations between baseline markers and FCDD. Results: Among 356 participants, 291 (81.7%) completed follow-up; among these 291 subjects, 109 (37.5%) experienced FCDD. 47 participants experienced fractures (16.2%), 27 developed diabetes (9.3%), 25 experienced cardiovascular events or mortality (8.6%). Stepwise regression identified osteocalcin (odds ratio: 0.938, 95% confidence interval: 0.895-0.980, Conclusion: Our study shows that baseline osteocalcin is independently associated with long-term FCDD outcomes in healthy women. These insights offer valuable guidance for the development of personalized health prevention and intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.